Search Results

The VIPER Spine System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine.

The VIPER Spine System is intended for noncervical pedicle fixation and nonpedicle fixation for the following indications: degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudoarthrosis; and failed previous fusion in skeletally mature patients.

When used in a posterior percutaneous approach with MIS instrumentation, the VIPER System is intended for noncervical pedicle fixation and nonpedicle fixation for the following indications: degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudoarthrosis; and failed previous fusion in skeletally mature patients.

This submission addresses additional rod components.

The provided document does not contain information regarding software or AI. It describes additions to a spinal implant system called VIPER™ Spine System. Therefore, I cannot extract information related to acceptance criteria, device performance, studies, sample sizes, ground truth, or expert involvement as these are not relevant to the content of this document.

The document discusses the regulatory approval (510(k) submission) of additional rod components for the VIPER™ Spine System, a medical device for spinal fixation. It details the device's intended use and materials, and mentions that "Performance data were submitted to characterize the subject VIPER™ Spine System components addressed in this notification." However, it does not provide the actual acceptance criteria, the results of the performance data, or details of any specific studies (e.g., sample sizes, ground truth establishment, expert involvement, or MRMC studies).

The FDA's letter states that they have reviewed the submission and find the device substantially equivalent to legally marketed predicate devices, allowing its marketing. This regulatory approval is based on the provided performance data, but the specifics of that data are not included in this extract.

Ask a specific question about this device